Tumor microenvironment features may predict immunotherapy response in rare cancers

A new study in Cell Reports Medicine from researchers at The University of Texas MD Anderson Cancer Center identified key ...

Kali Therapeutics Announces Oral Presentation of KT502, a Novel CD19 x CD3 T-Cell Engager, at the EULAR 2026 Annual Congress

Kali Therapeutics, a clinical-stage biotechnology company pioneering next-generation immune-resetting therapies, announced ...

Vyriad Launches G-Link: A Modular Platform Advancing T-Cell Targeted Lentiviral Vector Delivery for In Vivo and Ex Vivo Applications

Link is a first-in-class modular adaptor protein technology designed to enable and enhance T-cell-targeting delivery across ...
The Grand Junction Daily Sentinel

CD3 Dem candidates both made one-time contributions to Republican senators

There are similarities to be found between the two Democrats running for Colorado’s 3rd Congressional U.S. House District.

Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202

Context announces buyout of CT-202 future milestones and royalties in exchange for a fully paid-up, non-terminable licensePhase 1 initiation for ...
Aspen Daily News

Two Pitkin County residents face off in CD3 Dem primary

Two Roaring Fork Valley candidates are vying for the Democratic nomination for Colorado’s House District 3 seat in Congress.

Tiziana Announces New Positive Clinical Data for Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis

Favourable trends seen in stability of disability and clinically meaningful improvements in fatigue.BOSTON, May 19, 2026 ...
The Manila Times

Antengene Appoints Dr. Bing Hou as Chief Scientific Officer to Lead Innovation-Driven R&D Strategy and Advance Next-Generation Pipeline

SHANGHAI and HONG KONG, May 20, 2026 /PRNewswire/ -- Antengene Corporation Limited  ('Antengene', SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering ...
Multiple Sclerosis News Today

Foralumab shows promise in nonactive SPMS, EAP data suggest

Foralumab may help slow disability progression and ease fatigue in people with nonactive SPMS, per data from an early access ...

Antengene Corporation Limited: Antengene Appoints Dr. Bing Hou as Chief Scientific Officer to Lead Innovation-Driven R&D Strategy and Advance Next-Generation Pipeline

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech ...

Context Therapeutics Inc.: Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202

Context announces buyout of CT-202 future milestones and royalties in exchange for a fully paid-up, non-terminable license Phase 1 initiation for CT-202 trial expected in third quarter of 2026 PHILADE ...